NCT06199505View on ClinicalTrials.gov

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM

PHASE2CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

July 12, 2024

Conditions
Type 2 Diabetes
Interventions
DRUG

GZR101

Once daily

DRUG

insulin degledec/insulin aspart

Once daily or twice daily

Trial Locations (1)

100000

Gan & Lee Pharmaceuticals Co., Ltd, Beijing

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY

NCT06199505 - A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM | Biotech Hunter | Biotech Hunter